Abstract

Cryptococcus neoformans can cause fatal meningoencephalitis in patients with AIDS or other immunocompromising conditions. Current antifungals are suboptimal to treat this disease; therefore, novel targets and new therapies are needed. Previously, we have shown that chitosan is a critical component of the cryptococcal cell wall and is required for survival in the mammalian host and that chitosan deficiency results in rapid clearance from the mammalian host. We had also identified several specific proteins that were required for chitosan biosynthesis, and we hypothesize that screening for compounds that inhibit chitosan biosynthesis would identify additional genes/proteins that influence chitosan biosynthesis. To identify these compounds, we developed a robust and novel cell-based flow cytometry screening method to identify small-molecule inhibitors of chitosan production. We screened the ICCB Known Bioactives library and identified 8 compounds that reduced chitosan in C. neoformans We used flow cytometry-based counterscreens and confirmatory screens, followed by a biochemical secondary screen to refine our primary screening hits to 2 confirmed hits. One of the confirmed hits that reduced chitosan content was the aminoalkylindole BML-190, a known inverse agonist of mammalian cannabinoid receptors. We demonstrated that BML-190 likely targets the C. neoformans G-protein-coupled receptor Gpr4 and, via the cyclic AMP (cAMP)/protein kinase A (PKA) signaling pathway, contributes to an intracellular accumulation of cAMP that results in decreased chitosan. Our discovery suggests that this approach could be used to identify additional compounds and pathways that reduce chitosan biosynthesis and could lead to potential novel therapeutics against C. neoformansIMPORTANCECryptococcus neoformans is a fungal pathogen that kills ∼200,000 people every year. The cell wall is an essential organelle that protects fungi from the environment. Chitosan, the deacetylated form of chitin, has been shown to be an essential component of the cryptococcal cell wall during infection of a mammalian host. In this study, we screened a set of 480 compounds, which are known to have defined biological activities, for activity that reduced chitosan production in C. neoformans Two of these compounds were confirmed using an alternative method of measuring chitosan, and one of these was demonstrated to impact the cAMP signal transduction pathway. This work demonstrates that the cAMP pathway regulates chitosan biosynthesis in C. neoformans and validates that this screening approach could be used to find potential antifungal agents.

Highlights

  • Cryptococcus neoformans can cause fatal meningoencephalitis in patients with AIDS or other immunocompromising conditions

  • To identify small molecules that can inhibit chitosan production, we developed a cell-based phenotypic medium-throughput flow cytometry screen that was identified as robust, meaning that it has high precision and good dynamic range, based upon calculating the Z-prime, a calculation commonly used to assess the quality of higher-throughput screening assays [14]

  • We found that a dose-response of WIN 55,212-2 with the cyclic AMP (cAMP)/protein kinase A (PKA) pathway mutant strains resulted in an increase of chitosan in the wild type and gpr4⌬ strain, a decrease of chitosan from gpa1⌬ strains, but no effect on the cac1⌬ or pka1⌬ strain (Fig. 10)

Read more

Summary

Introduction

Cryptococcus neoformans can cause fatal meningoencephalitis in patients with AIDS or other immunocompromising conditions. We screened a set of 480 compounds, which are known to have defined biological activities, for activity that reduced chitosan production in C. neoformans Two of these compounds were confirmed using an alternative method of measuring chitosan, and one of these was demonstrated to impact the cAMP signal transduction pathway. Antimicrobial drug resistance is an identified concern when using the current antifungal therapies against cryptococcosis [6, 7] Overall, these concerns create the urgency for the discovery of novel targets for the development of effective drugs against the primary etiology of AIDS-related cryptococcal meningitis, Cryptococcus neoformans. Three C. neoformans strains have been engineered to be deficient in chitosan production, via gene deletions of CHS3, CSR2, or all three CDA genes Chitosan in these three strains was undetectable or very low by biochemical assay or using a chitosanspecific stain [9, 10]. These results identify chitosan as being important for C. neoformans virulence

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.